|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:ATCCode
|
J01AA12
|
|
gptkbp:CASNumber
|
220620-09-7
|
|
gptkbp:contraindication
|
hypersensitivity to tigecycline
|
|
gptkbp:drugClass
|
glycylcycline
|
|
gptkbp:eliminatedIn
|
biliary and renal
|
|
gptkbp:firstBook
|
glycylcycline antibiotics
|
|
gptkbp:form
|
powder for solution for infusion
|
|
gptkbp:genericName
|
gptkb:tigecycline
|
|
gptkbp:halfLife
|
27-43 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tygacil
|
|
gptkbp:indication
|
gptkb:community-acquired_bacterial_pneumonia
complicated intra-abdominal infections
complicated skin and skin structure infections
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:notEffectiveAgainst
|
gptkb:Pseudomonas_aeruginosa
gptkb:Proteus_species
gptkb:Providencia_species
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
71-89%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
increased mortality risk in certain infections
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:bfsParent
|
gptkb:Wyeth
|
|
gptkbp:bfsLayer
|
5
|